Close menu




October 25th, 2022 | 14:43 CEST

Core One Labs, XPhyto, BioNTech - The second biotech series moves forward

  • Biotechnology
Photo credits: pixabay.com

The enormously rapid development of the various COVID vaccines by historical standards showed how important biotechnology already is for humanity. Previously unknown companies such as BioNTech, Valneva and CureVac took center stage on the stock market and were able to multiply their share prices within a few months. Even after the pandemic, the biotech wheel continues to turn. Enormous growth opportunities are said to exist in the market for psychedelic drugs. Here, young growth companies are waiting in the wings with the potential to multiply their share prices in the future.

time to read: 4 minutes | Author: Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , XPHYTO THERAPEUTICS | CA98421R1055 , CORE ONE LABS INC. | CA21872J2083

Table of contents:


    Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.
    "[...] Defence will continue to develop its Antibody Drug Conjugates "ADC" and its radiopharmaceuticals programs, which are currently two of the hottest products in demand in the pharma industries where significant consolidations and take-overs occurred. [...]" Sébastien Plouffe, CEO, Founder and Director, Defence Therapeutics Inc.

    Full interview

     

    Infinite growth market

    While the growth curve for vaccine manufacturers against COVID-19 may have already peaked last year, the global market for psychedelic drugs is still in the early stages of a steep growth curve. Between 2022 and 2029, market research firm Data Bridge Market Research projects a compound annual growth rate of 13%. That would equate to an increase in market volume from the current USD 2.39 billion to USD 6.40 billion by then.

    There are approximately 350 million people living with depression in the world. According to estimates by the World Health Organization (WHO), only one in four sufferers receives adequate treatment. This makes depression the most important cause of illness of all. Apart from prescribing antidepressants, which usually have severe side effects, there are currently few alternative treatment methods. For some years now, however, the "mental health" sector has been revolutionized, primarily by innovative biotech companies.

    In addition to the top dog Compass Pathways, which reigns supreme with a market capitalization of USD 415.87 million, more and more smaller development companies such as XPhyto or Core One Labs are conducting research in this segment. Vancouver-based Core One Labs, which currently has a market cap of CAD 34.18 million, is focused on bringing psychedelic medicines to market through the development and production of psychedelic compounds, advancing assisted treatments, and integrating new drug delivery technologies. In doing so, the Canadians are taking a multi-faceted business approach, integrating multiple complementary business units and entities to establish themselves as an industry leader in the rapidly growing and emerging psychedelics market.

    Core One Labs seeks big brother

    For example, Core One Labs, through its wholly-owned subsidiary Vocan Biotechnologies Inc. developed a patent-pending proprietary psilocybin production system using modified bacteria. In addition, the Company holds four provisional patents for the development of psychedelic-based pharmaceutical formulations targeting neurological and mental disorders under its wholly owned subsidiary Akome Biotech Ltd. and three provisional patents under its other wholly owned subsidiary, Awaken BioSciences Inc. for additional synthetic technologies for psilocybin and psilocin production methods.

    It has now been announced that the current path will not be continued alone. Core One is actively seeking investment and potential acquisition opportunities by strategic psychedelics or pharmaceutical companies. Once a suitable offer is received and an agreement is reached, the Company will inform shareholders and the market and provide all necessary details of the transaction. According to management, an acquisition could represent a unique opportunity for Core One and its shareholders to enter new markets and product lines, and for Core One to benefit from the strengths and synergies of a buyer. This, in turn, could increase Core One's market share and strengthen its competitive advantage in the lucrative and fast-growing psychedelics industry. From a technical perspective, the chart formed a saucer formation in recent months. A breakout above the CAD 1.21 level would open up a price potential of around 88% to CAD 2.32.

    XPhyto - Broad-based accelerator

    Unlike Core One, German-Canadian company XPhyto is not actively seeking buyers for its highly scalable platform technology. However, assuming further research successes, interest from major players in the biotech or pharma industries could steadily increase. In all three business areas, significant successes have been recorded in recent weeks.

    For example, the diversified bioscience accelerator, which focuses on next-generation drug formulations, diagnostics, and new active pharmaceutical ingredients, submitted a patent application for its substantial collection of novel psychedelic compounds. Here, the compound database can be targeted for the treatment of neuropsychiatric, neurodegenerative and neuroinflammatory disorders, including depression, tobacco, opiate and cocaine addiction, or alcoholism, among others.

    In addition, XPhyto reported positive in vivo results of a Rotigotine transdermal patch for the treatment of Parkinson's disease. Rotigotine is an active ingredient already approved in Europe and the US for the treatment of Parkinson's disease and restless legs syndrome (RLS). Here, XPhyto compared an active ingredient patch currently on the market with the patch developed by its German subsidiary Vektor Pharma TF GmbH. The results for the criteria "penetration of the skin" as well as "dissolution behavior of the active ingredient" clearly exceeded the predictions. Thus, nothing should stand in the way of transferring the developed Rotigotine patch to an in vivo study. If the study progresses positively, it should then be another 6 to 12 months before market launch. A detailed background is available at researchanalyst.com.

    In the third sector, the Diagnostics Division, a binding letter of intent was also signed with a US company to cooperate in the field of thin-film screening tests. The partnership is to revolve around manufacturing, distribution, research and development with the group, which has production capacities that meet the requirements of the US Food and Drug Administration.

    From a chart perspective, XPhyto's stock has also been able to form a saucer formation in recent months, trading at CAD 0.49 on the Toronto Stock Exchange. A break of resistance at CAD 0.56 would also open up significant upside potential to the CAD 0.70 area.


    The biotech sector corrected strongly in recent weeks, and the growth potential, especially in second-tier stocks, is enormous. While Core One Labs is actively looking for a buyer, XPhyto is rushing from success to success in its three business areas.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Stefan Feulner

    The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
    He is passionate about analyzing a wide variety of business models and investigating new trends.

    About the author



    Related comments:

    Commented by Fabian Lorenz on November 7th, 2024 | 07:15 CET

    TUI, Evotec, BioNxt Solutions: Short squeeze potential, Price drops, and Momentum

    • Biotechnology
    • Biotech
    • Travel

    BioNxt Solutions' stock has gained 50% since the end of August. The chances are good that the momentum will continue for the biotech company. The stock would need to more than double to reach its January level. The industry environment is favorable, the news flow is positive, and takeover speculation exists. Takeover speculation is perhaps the only positive factor for Evotec's share at the moment. The operational development is certainly not. Yesterday, the Company reported a significant drop in earnings. Is there any improvement in sight? Operationally, TUI has been doing well for quite some time. With a jump in the share price, the stock is now setting its sights on the resistance at EUR 8. Could there even be a short squeeze? Analysts may also shift to the bull camp.

    Read

    Commented by Juliane Zielonka on November 7th, 2024 | 07:00 CET

    Vidac Pharma, BioNTech, Bayer - Billion-Dollar Gene Therapy Market Attracts Investors

    • Biotechnology
    • Biotech
    • Pharma

    Two trends are emerging in the pharmaceutical industry: personalized medicine, which tailors therapies to the genetic profile of individual patients, and the development of highly specific active ingredients that target biological mechanisms. Vidac Pharma is one of the companies focusing on these targeted therapies and recently received a groundbreaking US patent for its innovative approach to normalizing cancer cell metabolism - a concept known as the "Warburg effect reversal." BioNTech is driving its transformation from COVID-19 vaccine producer to cancer specialist, with promising Phase II trials underway for treatments targeting lung and breast cancers. Bayer, meanwhile, is under pressure due to disappointing sales of its partner Regeneron's eye drug Eylea® – the second most important product in the portfolio, which has to hold its own against growing competition. Where is an investment worthwhile?

    Read

    Commented by André Will-Laudien on November 6th, 2024 | 08:00 CET

    US election and the biotech sector – A hot November is on the cards! BioNTech, Pfizer, Nyxoah, Bayer or Evotec?

    • Biotechnology
    • Biotech
    • Pharma

    With anticipation building for both the Q3 earnings season and the US election results, the markets are in a wait-and-see mode. Democrat frontrunner Kamala Harris is said to be committed to continuing the successful policies of her predecessor Joe Biden. Of course, science, research and climate protection are in the spotlight. Her rival, Donald Trump, is said to be more concerned with strengthening the traditional economy, where automotive engineering, the defense industry and security companies come to the fore. Additionally, markets are looking to central banks for cues, as lower interest rates would be a boon for the biotech sector. Here are some investment ideas for dynamic investors in this promising climate.

    Read